(1S,2S)-(+)-trans-2-aminocyclohexanecarboxylic acid ethyl ester hydrochloride | 180979-18-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1S,2S)-(+)-trans-2-aminocyclohexanecarboxylic acid ethyl ester hydrochloride
• 英文别名: Ethyl (1S,2S)-2-aminocyclohexane-1-carboxylate hydrochloride；ethyl (1S,2S)-2-aminocyclohexane-1-carboxylate;hydrochloride
• CAS: 180979-18-4
• 化学式: C₉H₁₇NO₂*ClH
• 分子量: 207.7
• InChiKey: XMQSOBPCWYVZSW-WSZWBAFRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.49
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1S,2S)-(+)-trans-2-aminocyclohexanecarboxylic acid ethyl ester hydrochloride 在 水 、 苯硫酚 、 三乙胺 、 sodium hydroxide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 trans-2-(methylamino)cyclohexanecarboxylic acid
  参考文献：
  名称：

  Selective mGAT2 (BGT-1) GABA Uptake Inhibitors: Design, Synthesis, and Pharmacological Characterization

  摘要：

  beta-Amino acids sharing a lipophilic diaromatic side chain were synthesized and characterized pharmacologically on mouse GABA transporter subtypes mGAT1-4. The parent amino acids were also characterized. Compounds 13a, 13b, and 17b displayed more than 6-fold selectivity for mGAT2 over mGAT1. Compound 17b displayed anticonvulsive properties inferring a role of mGAT2 in epileptic disorders. These results provide new neuropharmacological tools and a strategy for designing subtype selective GABA transport inhibitors.

  DOI：

  10.1021/jm301872x
• 作为产物：
  描述：

  乙醇 、 (1S,2S)-trans-1,2-cyclohexanedicarboxylic anhydride 在 叠氮基三甲基硅烷 、 水 、 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.17h， 以57%的产率得到(1S,2S)-(+)-trans-2-aminocyclohexanecarboxylic acid ethyl ester hydrochloride
  参考文献：
  名称：

  Selective mGAT2 (BGT-1) GABA Uptake Inhibitors: Design, Synthesis, and Pharmacological Characterization

  摘要：

  beta-Amino acids sharing a lipophilic diaromatic side chain were synthesized and characterized pharmacologically on mouse GABA transporter subtypes mGAT1-4. The parent amino acids were also characterized. Compounds 13a, 13b, and 17b displayed more than 6-fold selectivity for mGAT2 over mGAT1. Compound 17b displayed anticonvulsive properties inferring a role of mGAT2 in epileptic disorders. These results provide new neuropharmacological tools and a strategy for designing subtype selective GABA transport inhibitors.

  DOI：

  10.1021/jm301872x

文献信息

• [EN] BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS<br/>[FR] DÉRIVÉS DE BIPHÉNYL-ÉTHYL-PYRROLIDINE EN TANT QUE MODULATEURS DES RÉCEPTEURS H3 DE L'HISTAMINE POUR LE TRAITEMENT DE TROUBLES COGNITIFS
  申请人：ARENA PHARM INC

  公开号：WO2014110103A1

  公开（公告）日：2014-07-17

  The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that modulate the activity of the histamine H3 receptor (Ia). Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders.

  本发明涉及式(Ia)的化合物及其药用可接受的盐、溶剂合物和水合物，其调节组胺H3受体(Ia)的活性。本发明的化合物和药物组合物用于治疗组胺H3相关疾病的方法。
• Preparation of uracil by cycloreversion. Structure of cycloalkane/ene- and norbornane/ene-fused dihydrouracils
  作者：Samuel Frimpong-Manso、Katalin Nagy、Géza Stájer、Gábor Bernáth、Pál Sohár

  DOI：10.1002/jhet.5570290140

  日期：1992.1

  formed from trans-4-cyclohexene-1-carboxylate, furnished the cis-fused 5,6-dihydropyrimidine-2,4(1H,3H)-dione. On heating, the norbornene-diexo-fused dihydrouracil 16 yielded 2,4-pyrimidinedione through the splitting-off of cyclopentadiene. The structures of the compounds were proved by 1H and 13C nmr spectroscopy.

  2-氨基-1-环烷烃，环烯烃，降冰片烷和降冰片烯羧酸酯1–9与氰酸钾的反应生成脲酯，然后将其酯化成环烷烃，环烯，降冰片烷和降冰片烯稠合的5,6-。二氢尿嘧啶10-17。在环化中，由反式-4-环己烯-1-羧酸酯形成的脲酯提供了顺式稠合的5,6-二氢嘧啶-2,4（1 H，3 H）-二酮。加热时，降冰片烯-二烯基稠合的二氢尿嘧啶16通过环戊二烯的分解产生2，4-嘧啶二酮。化合物的结构由1 H和13证明C nmr光谱。
• Substituted piperazine cyclohexane carboxilic acid amides and the use thereof
  申请人：Bischoff Erwin

  公开号：US20050054637A1

  公开（公告）日：2005-03-10

  The present invention relates to substituted piperazinecyclohexanecarboxamides of the formula (I) to processes for their preparation and to their use in pharmaceuticals, in particular for the prophylaxis and/or treatment of cardiovascular disorders.

  本发明涉及式(I)的取代哌嗪环己烷羧酰胺，以及它们的制备过程和在制药学中的应用，特别是用于预防和/或治疗心血管疾病。
• SULFONAMIDE DERIVATIVE AND USE THEREOF
  申请人：Fukumoto Shoji

  公开号：US20140024650A1

  公开（公告）日：2014-01-23

  Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

  提供了一种具有AMPA受体功能增强作用的化合物，可用作预防或治疗抑郁症、阿尔茨海默病、精神分裂症、注意力缺陷多动障碍（ADHD）等药物。该化合物由式（I）表示：其中每个符号如本说明书所定义，或其盐。
• BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS
  申请人：ARENA PHARMACEUTICALS, INC.

  公开号：US20150353488A1

  公开（公告）日：2015-12-10

  The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that modulate the activity of the histamine H3 receptor (Ia). Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders.

  本发明涉及公式（Ia）的化合物及其药学上可接受的盐、溶剂和水合物，该化合物调节组胺H3受体（Ia）的活性。本发明的化合物及其制药组合物适用于治疗组胺H3相关疾病的方法。